Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationEBIATReceivables - NetReceivables - OtherShares IssuedShares OutstandingShares Outstanding
Ratios

Cardiol Therapeutics (CRDL) Receivables - Net (2020 - 2026)

Cardiol Therapeutics filings provide 3 years of Receivables - Net readings, the most recent being $154650.9 for Q4 2022.

  • On a quarterly basis, Receivables - Net rose 196.53% to $154650.9 in Q4 2022 year-over-year; TTM through Dec 2022 was $154650.9, a 196.53% increase, with the full-year FY2022 number at $154650.9, up 196.53% from a year prior.
  • Receivables - Net hit $154650.9 in Q4 2022 for Cardiol Therapeutics, up from -$67764.3 in the prior quarter.
  • In the past five years, Receivables - Net ranged from a high of $154650.9 in Q4 2022 to a low of -$87642.1 in Q2 2021.
  • Median Receivables - Net over the past 3 years was -$30707.2 (2021), compared with a mean of -$10179.8.
  • Biggest five-year swings in Receivables - Net: surged 1073.68% in 2021 and later dropped 29.64% in 2022.
  • Cardiol Therapeutics' Receivables - Net stood at $4443.5 in 2020, then surged by 1073.68% to $52153.1 in 2021, then surged by 196.53% to $154650.9 in 2022.
  • The last three reported values for Receivables - Net were $154650.9 (Q4 2022), -$67764.3 (Q3 2022), and -$46778.9 (Q2 2022) per Business Quant data.